CN114845711B - Raf激酶的抑制剂 - Google Patents
Raf激酶的抑制剂 Download PDFInfo
- Publication number
- CN114845711B CN114845711B CN202080090257.4A CN202080090257A CN114845711B CN 114845711 B CN114845711 B CN 114845711B CN 202080090257 A CN202080090257 A CN 202080090257A CN 114845711 B CN114845711 B CN 114845711B
- Authority
- CN
- China
- Prior art keywords
- carboxamide
- trifluoroethyl
- pyrrolidine
- methylphenyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962925596P | 2019-10-24 | 2019-10-24 | |
| US62/925,596 | 2019-10-24 | ||
| US202063044898P | 2020-06-26 | 2020-06-26 | |
| US63/044,898 | 2020-06-26 | ||
| PCT/US2020/057132 WO2021081375A1 (en) | 2019-10-24 | 2020-10-23 | Inhibitors of raf kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114845711A CN114845711A (zh) | 2022-08-02 |
| CN114845711B true CN114845711B (zh) | 2024-10-01 |
Family
ID=75619376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080090257.4A Active CN114845711B (zh) | 2019-10-24 | 2020-10-23 | Raf激酶的抑制剂 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11098031B1 (https=) |
| EP (1) | EP4048259A4 (https=) |
| JP (1) | JP7626910B2 (https=) |
| KR (1) | KR20220104702A (https=) |
| CN (1) | CN114845711B (https=) |
| AU (1) | AU2020371727B2 (https=) |
| BR (1) | BR112022007612A2 (https=) |
| CA (1) | CA3158530A1 (https=) |
| CL (1) | CL2022000998A1 (https=) |
| CO (1) | CO2022006712A2 (https=) |
| IL (1) | IL292424B1 (https=) |
| MX (1) | MX2022004937A (https=) |
| PH (1) | PH12022550976A1 (https=) |
| TW (1) | TWI899110B (https=) |
| WO (1) | WO2021081375A1 (https=) |
| ZA (1) | ZA202204284B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202106684A (zh) | 2019-05-03 | 2021-02-16 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
| JP7626910B2 (ja) | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Ｒａｆキナーゼの阻害剤 |
| JP7214925B2 (ja) * | 2019-12-06 | 2023-01-30 | メッドシャイン ディスカバリー インコーポレイテッド | Ｐａｎ－ＲＡＦキナーゼ阻害剤としてのビアリール化合物 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2022060996A1 (en) * | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| BR112023021913A2 (pt) * | 2021-04-23 | 2024-01-16 | Kinnate Biopharma Inc | Tratamento de câncer com inibidor de raf |
| EP4326255A4 (en) * | 2021-04-23 | 2025-03-12 | Pierre Fabre Medicament | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof |
| EP4373806A4 (en) * | 2021-07-19 | 2025-06-18 | Pierre Fabre Medicament | Preparation method of 3- (2, 2, 2-trifluoroethyl) pyrrolidine hydrochloride |
| WO2023061492A1 (zh) * | 2021-10-14 | 2023-04-20 | 华领医药技术（上海）有限公司 | 2-氧代-3-氮杂双环[3.1.0]己烷衍生物 |
| WO2023070053A1 (en) * | 2021-10-21 | 2023-04-27 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| CA3240192A1 (en) * | 2021-12-09 | 2023-06-15 | Daniel L. Flynn | Raf kinase inhibitors and methods of use thereof |
| CA3240263A1 (en) | 2021-12-09 | 2023-06-15 | Daniel L. Flynn | Raf kinase inhibitors and methods of use thereof |
| EP4472968A1 (en) * | 2022-02-03 | 2024-12-11 | Pierre Fabre Medicament | Inhibitors of raf kinases |
| EP4486722A4 (en) * | 2022-03-02 | 2026-03-25 | Nico Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND PROCESSES |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020198058A1 (en) * | 2019-03-22 | 2020-10-01 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| EA018551B1 (ru) | 2008-02-22 | 2013-08-30 | Айрм Ллк | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-KIT И PDGFR |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| SI3366293T1 (sl) | 2012-06-07 | 2020-08-31 | Deciphera Pharmaceuticals, Llc | Dihidronafthiridini in sorodne spojine uporabne kot kinazni inhibitorji za zdravljenje proliferativnih bolezni |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| EP3191467B1 (en) | 2014-09-12 | 2020-10-21 | Novartis AG | Compounds and compositions as kinase inhibitors |
| CN107074828B (zh) * | 2014-09-12 | 2020-05-19 | 诺华股份有限公司 | 用作raf激酶抑制剂的化合物和组合物 |
| CA3026876A1 (en) | 2016-06-10 | 2017-12-14 | Novartis Ag | Therapeutic uses of a c-raf inhibitor |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| WO2020168172A1 (en) | 2019-02-15 | 2020-08-20 | Zamboni Chem Solutions Inc. | Conjugate compounds for the degradation of raf |
| TW202106684A (zh) | 2019-05-03 | 2021-02-16 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
| JP7626910B2 (ja) | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Ｒａｆキナーゼの阻害剤 |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| BR112023021913A2 (pt) | 2021-04-23 | 2024-01-16 | Kinnate Biopharma Inc | Tratamento de câncer com inibidor de raf |
| EP4326255A4 (en) | 2021-04-23 | 2025-03-12 | Pierre Fabre Medicament | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof |
-
2020
- 2020-10-23 JP JP2022523904A patent/JP7626910B2/ja active Active
- 2020-10-23 BR BR112022007612A patent/BR112022007612A2/pt unknown
- 2020-10-23 PH PH1/2022/550976A patent/PH12022550976A1/en unknown
- 2020-10-23 TW TW109136965A patent/TWI899110B/zh active
- 2020-10-23 US US17/079,152 patent/US11098031B1/en active Active
- 2020-10-23 IL IL292424A patent/IL292424B1/en unknown
- 2020-10-23 EP EP20878472.8A patent/EP4048259A4/en active Pending
- 2020-10-23 AU AU2020371727A patent/AU2020371727B2/en active Active
- 2020-10-23 CA CA3158530A patent/CA3158530A1/en active Pending
- 2020-10-23 MX MX2022004937A patent/MX2022004937A/es unknown
- 2020-10-23 KR KR1020227016515A patent/KR20220104702A/ko active Pending
- 2020-10-23 CN CN202080090257.4A patent/CN114845711B/zh active Active
- 2020-10-23 WO PCT/US2020/057132 patent/WO2021081375A1/en not_active Ceased
-
2021
- 2021-03-25 US US17/213,036 patent/US12312336B2/en active Active
-
2022
- 2022-04-14 ZA ZA2022/04284A patent/ZA202204284B/en unknown
- 2022-04-21 CL CL2022000998A patent/CL2022000998A1/es unknown
- 2022-05-20 CO CONC2022/0006712A patent/CO2022006712A2/es unknown
-
2025
- 2025-04-18 US US19/183,462 patent/US20260055084A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020198058A1 (en) * | 2019-03-22 | 2020-10-01 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| CN113874381A (zh) * | 2019-03-22 | 2021-12-31 | 金耐特生物制药公司 | Raf激酶的抑制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114845711A (zh) | 2022-08-02 |
| US20260055084A1 (en) | 2026-02-26 |
| US12312336B2 (en) | 2025-05-27 |
| AU2020371727A1 (en) | 2022-05-26 |
| ZA202204284B (en) | 2024-09-25 |
| CL2022000998A1 (es) | 2023-02-10 |
| CO2022006712A2 (es) | 2022-05-31 |
| KR20220104702A (ko) | 2022-07-26 |
| BR112022007612A2 (pt) | 2022-09-20 |
| MX2022004937A (es) | 2022-07-27 |
| AU2020371727B2 (en) | 2026-01-22 |
| TWI899110B (zh) | 2025-10-01 |
| US20210300904A1 (en) | 2021-09-30 |
| PH12022550976A1 (en) | 2023-09-25 |
| JP7626910B2 (ja) | 2025-02-05 |
| CA3158530A1 (en) | 2021-04-29 |
| EP4048259A1 (en) | 2022-08-31 |
| EP4048259A4 (en) | 2023-08-02 |
| WO2021081375A1 (en) | 2021-04-29 |
| NZ788005A (en) | 2024-10-25 |
| TW202128680A (zh) | 2021-08-01 |
| IL292424A (en) | 2022-06-01 |
| IL292424B1 (en) | 2026-02-01 |
| JP2022554169A (ja) | 2022-12-28 |
| US11098031B1 (en) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114845711B (zh) | Raf激酶的抑制剂 | |
| KR20250095617A (ko) | 신규한 트리헤테로사이클릭 화합물｛Novel triheterocyclic compounds｝ | |
| EP3442947A1 (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| TW202231633A (zh) | Cdk抑制劑 | |
| JP2021529740A (ja) | サイクリン依存性キナーゼの阻害剤 | |
| EA039783B1 (ru) | ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ | |
| JP7253086B2 (ja) | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 | |
| CN113874381A (zh) | Raf激酶的抑制剂 | |
| CN120548308A (zh) | Kif18a的抑制剂及其用途 | |
| CA3246087A1 (en) | HETEROCYCLIC COMPOUNDS AS BCL6 MODULATORS FOR USE AS DEGRADING AGENTS DIRECTED AGAINST A LIGAND | |
| WO2024102621A1 (en) | Akt1 modulators | |
| BR112020010012A2 (pt) | compostos de pirazolopiridinona | |
| JP7349570B2 (ja) | Ｍ４作動薬としての２－アザスピロ［３．４］オクタン誘導体 | |
| CN116322692A (zh) | 自分泌运动因子抑制剂化合物 | |
| TW202204342A (zh) | Ｎ—（雜環基及雜環基烷基）—３—苯甲基吡啶—２—胺衍生物 | |
| JP2022551853A (ja) | Ｍ４作動薬としての５－オキサ－２－アザスピロ［３．４］オクタン誘導体 | |
| CN119156385A (zh) | 稠合双环杂芳族化合物及其在治疗癌症中的用途 | |
| HK40077347A (zh) | Raf激酶的抑制剂 | |
| HK40063842A (en) | Inhibitors of raf kinases | |
| HK40077347B (zh) | Raf激酶的抑制剂 | |
| EA052498B1 (ru) | Гетероциклические соединения в качестве модуляторов bcl6 как лиганд-направленных деградеров |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40077347 Country of ref document: HK |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240906 Address after: Laval, France Applicant after: PIERRE FABRE MEDICAMENT Country or region after: France Address before: California, USA Applicant before: Jinnaite biopharmaceutical Co. Country or region before: U.S.A. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |